Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 6, 2019 Off

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) – Pipeline Review, H1 2019” drug…

May 6, 2019 Off

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019” drug pipelines…

May 6, 2019 Off

Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) – Pipeline Review, H1 2019” drug pipelines…

May 6, 2019 Off

Hospital Acquired Pneumonia (HAP) Pipeline Review, H1 2019 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. This…

May 6, 2019 Off

Dr. Reddy’s Laboratories Announces the Launch of Testosterone Gel, 1.62% (20.25 mg/1.25 g Pump Actuation) in the U.S. Market

By BusinessWire

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…

GenSight Biologics to present Data from the Reverse Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
May 6, 2019 Off

GenSight Biologics to present Data from the Reverse Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

By BusinessWire

GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting

UroGen Phase 3 OLYMPUS Trial shows UGN-101 as an initial kidney-sparing treatment option for low-gradeUTUC
May 5, 2019 Off

UroGen Phase 3 OLYMPUS Trial shows UGN-101 as an initial kidney-sparing treatment option for low-gradeUTUC

By BusinessWire

59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635
May 3, 2019 Off

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635

By BusinessWire

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,announced that on May 3, 2019 the Compensation Committee of Puma’s Boardof Directors approved the grant of inducement restricted stock unitawards covering an aggregate of 49,125 shares of Puma common stock tonine new non-executive employees.

Dicerna approves purchase of 145,500 shares of common stock to bedistributed among eight new employees
May 3, 2019 Off

Dicerna approves purchase of 145,500 shares of common stock to bedistributed among eight new employees

By BusinessWire

Dicerna Pharmaceuticals Board of Directors approved the grant of inducement stockoptions to purchase a total of 145,500 shares of common stock to bedistributed among eight new employees

FDA Approves Genentech’s Kadcyla for Adjuvant Treatment HER2-Positive Early Breast Cancer
May 3, 2019 Off

FDA Approves Genentech’s Kadcyla for Adjuvant Treatment HER2-Positive Early Breast Cancer

By BusinessWire

Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer

Posts pagination

Previous 1 … 3,225 3,226 3,227 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine